Browse > Article
http://dx.doi.org/10.4014/jmb.1107.07057

Construction of Novel Bifunctional Chimeric Proteins Possessing Antitumor and Thrombolytic Activities  

Hui, Jing (Laboratory of Biomaterials and Biopharmaceuticals, School of Life Sciences, Liaoning University)
Dai, Youjin (Laboratory of Biomaterials and Biopharmaceuticals, School of Life Sciences, Liaoning University)
Bian, Yuanyuan (Laboratory of Biomaterials and Biopharmaceuticals, School of Life Sciences, Liaoning University)
Li, Hui (Laboratory of Biomaterials and Biopharmaceuticals, School of Life Sciences, Liaoning University)
Cui, Xiaojin (Laboratory of Biomaterials and Biopharmaceuticals, School of Life Sciences, Liaoning University)
Yu, Xiaojie (Laboratory of Biomaterials and Biopharmaceuticals, School of Life Sciences, Liaoning University)
You, Song (College of Pharmaceutical Engineering, Shenyang Pharmaceutical University)
Hu, Fengqing (Laboratory of Biomaterials and Biopharmaceuticals, School of Life Sciences, Liaoning University)
Publication Information
Journal of Microbiology and Biotechnology / v.22, no.7, 2012 , pp. 894-901 More about this Journal
Abstract
Based on their respective antitumor and thrombolytic activities, the superantigen staphylococcal enterotoxin C2 (SEC2) and staphylokinase (Sak) were chosen for the construction of the novel chimeric proteins Sak-linker-SEC2 and SEC2-linker-Sak using a linker composed of nine Ala residues. Both chimeric proteins possessed nearly the same PBMC proliferation stimulating activity and antitumor activity as SEC2 and thrombolytic activity as Sak. Neither the SEC2 or Sak component of each chimeric protein affected the activity of the other component. The results presented in this study provide a possible strategy to prevent and cure tumor thrombus.
Keywords
Chimeric protein; antitumor; thrombolytic; staphylokinase; staphylococcal enterotoxin C2;
Citations & Related Records

Times Cited By Web Of Science : 0  (Related Records In Web of Science)
연도 인용수 순위
  • Reference
1 Andreescu, A. C. M., M. Cushman, J. M. Hammond, and M. E. Wood. 2001. Trousseau's syndrome treated with long-term subcutaneous lepirudin (case report and review of the literature). J. Thromb. Thrombolys. 11: 33-37.   DOI   ScienceOn
2 Abrahmsen, L. 1995. Superantigen engineering. Curr. Opin. Struct. Biol. 5: 464-470.   DOI   ScienceOn
3 Alpaugh, R. K., J. Schultz, C. McAleer, B. J. Giantonio, R. Persson, M. Burnite, et al. 1998. Superantigen-targeted therapy: Phase I escalating repeat dose trial of the fusion protein PNU-214565 in patients with advanced gastrointestinal malignancies. Clin. Cancer Res. 4: 1903-1914.
4 Baker, M. D. and K. R. Acharya. 2004. Superantigens: Structure-function relationships. Int. J. Med. Microbiol. 293: 529-537.   DOI   ScienceOn
5 Bokarewa, M. I., T. Jin, and A. Tarkowski. 2006. Staphylococcus aureus: Staphylokinase. Int. J. Biochem. Cell Biol. 38: 504-509   DOI   ScienceOn
6 Brener, S. J. and E. J. Topol. 1998. Third-generation Thrombolytic Agents for Acute Myocardial Infarction. Marcel Dekker Inc., New York.
7 Chen, T. Z. 2001. The exploitation of HAS and its application in tumor therapy. Prog. Microbiol. Immunol. 29: 63-69.
8 Chen, T. Z. 2005. Gaojusheng: A novel anti-cancer drug prepared from SEC superantigen. Prog. Microbiol. Immunol. 33: 49-50.
9 Chew, H. K., T. Wun, D. Harvey, H. Zhou, and R. H. White. 2006. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch. Intern. Med. 166: 458-464.
10 Collen, D., B. Schlott, Y. Engelborghs, B. Van Hoet, M. Hartmann, H. R. Lijnen, and D. Behnke. 1993. On the mechanism of the activation of human plasminogen by recombinant staphylokinase. J. Biol. Chem. 268: 8284-8289.
11 Dohlsten, M., A. Sundstedt, M. Bjorklund, G. Hedlund, and J. Kalland. 1993. Superantigen-induced cytokines suppress growth of human colon-carcinoma cells. Int. J. Cancer 54: 482-488.   DOI   ScienceOn
12 Grossman, D., J. G. Lamphear, J. A. Mollick, M. J. Betley, and R. R. Rich. 1992. Dual roles for class II major histocompatibility complex molecules in staphylococcal enterotoxin-induced cytokine production and in vivo toxicity. Infect. Immun. 60: 5190-5196.
13 Hansson, J., L. Ohlsson, R. Persson, G. Andersson, N. G. Ilbäck, M. J. Litton, et al. 1997. Genetically engineered superantigens as tolerable antitumor agents. Proc. Natl. Acad. Sci. USA 94: 2489-2494.   DOI   ScienceOn
14 Hedlund, G., M. Dohlsten, C. Petersson, and T. Kalland. 1993. Superantigen-based tumor therapy: In vivo activation of cytotoxic T cells. Cancer Immunol. Immunother. 36: 89-93.   DOI   ScienceOn
15 Herman, A., J. W. Kappler, P. Marrack, and A. M. Pullen. 1991. Superantigens: Mechanism of T-cell stimulation and role in immune responses. Annu. Rev. Immunol. 9: 745-772.   DOI   ScienceOn
16 Kwaan, H. C. and B. Vicuna. 2007. Thrombosis and bleeding in cancer patients. Oncol. Rev. 1: 14-27.   DOI   ScienceOn
17 Hui, J., Y. Cao, F. Xiao, J. Zhang, H. Li, and F. Q. Hu. 2008. Staphylococcus aureus enterotoxin C2 mutants: Biological activity assay in vitro. J. Ind. Microbiol. Biotechnol. 35: 975-980   DOI   ScienceOn
18 Johnson, H. M., J. K. Russell, and C. H. Pontzer. 1991. Staphylococcal enterotoxin microbial superantigens. FASEB J. 5: 2706-2712.
19 Kakkar, A. K. 2009. Antithrombotic therapy and survival in cancer patients. Best Pract. Res. Clin. Haematol. 22: 147-151.   DOI   ScienceOn
20 Lip, G. Y., B. S. Chin, and A. D. Blann. 2002. Cancer and the prothrombotic state. Lancet Oncol. 3: 27-34.   DOI   ScienceOn
21 Ma, W. X., H. Yu, Q. Q. Wang, J. F. Bao, J. Yan and H. Jin. 2004. In vitro biological activities of transmembrane superantigen staphylococcal enterotoxin A fusion protein. Cancer Immunol. Immuother. 53: 118-124.   DOI   ScienceOn
22 Mandi, N., S. Soorapaneni, S. Rewanwar, P. Kotwal, B. Prasad, G. Mandal, and S. Padmanabhan. 2009. High yielding recombinant staphylokinase in bacterial expression, purification and activity studies. Protein Expr. Purif. 64: 69-75.   DOI   ScienceOn
23 Matsumoto, K., K. Takase, Y. Yamamoto, Y. Doi, and S. Taguchi. 2009. Chimeric enzyme composed of polyhydroxyalkanoate (PHA) synthases from Ralstonia eutropha and Aeromonas caviae enhances production of PHAs in recombinant Escherichia coli. Biomacromolecules 10: 682-685.   DOI   ScienceOn
24 Mondal, T. K., D. Bhatta, S. Biswas, and P. Pal. 2002. Superantigen-induced apoptotic death of tumor cells is mediated by cytotoxic lymphocytes, cytokines, and nitric oxide. Biochem. Biophys. Res. Commun. 290: 1336-1342.   DOI   ScienceOn
25 Saksela, O. 1981. Radial caseinolysis in agarose: A simple method for detection of plasminogen activator in the presence of inhibitory substances and serum. Anal. Biochem. 111: 276-282   DOI   ScienceOn
26 Ochi, A., K. Migita, J. Xu, and K. Siminovitch. 1993. In vivo tumor immunotherapy by a bacterial superantigen. J. Immunol. 151: 3180-3186.
27 Pardoll, D. M. 1995. Paracrine cytokine adjuvants in cancer immunotherapy. Annu. Rev. Immunol. 13: 399-415.   DOI   ScienceOn
28 Rickles, F. R. and M. N. Levine. 2001. Epidemiology of thrombosis in cancer. Acta Haematol. 106: 6-12.   DOI   ScienceOn
29 Sambrook, J. and D. W. Russell. 2001. Molecular Cloning: A Laboratory Manual, 3rd Ed. Cold Spring Harbor Laboratory Press, New York.
30 Scholl, P. R., N. Trede, T. A. Chatila, and R. S. Geha. 1992. Role of protein tyrosine phosphorylation in monokine induction by the staphylococcal superantigen toxic shock syndrome toxin-1. J. Immunol. 148: 2237-2241.
31 Sundstedt, A., M. Celander, and G. Hedlund. 2008. Combining tumor-targeted superantigens with interferon-alpha results in synergistic anti-tumor effects. Int. Immunopharmacol. 8: 442-452   DOI   ScienceOn
32 Toombs, C. F. 2001. New directions in thrombolytic therapy. Curr. Opin. Pharmacol. 1: 164-168.   DOI   ScienceOn
33 Verstraete, M. 2000. Third-generation thrombolytic drugs. Am. J. Med. 109: 52-58.   DOI   ScienceOn
34 Wang, J. Z. and M. Fan. 2002. Manual of Protein Technology. Science Press, Beijing.
35 Xu, M. K. and C. G. Zhang. 2006. Gene expression and function study of fusion immunotoxin anti-Her-2-scFv-SEC2 in Escherichia coli. Appl. Microbiol. Biotechnol. 70: 78-84.   DOI   ScienceOn